Ahmed N K, Gaddis R R, Tennant K D, Lacz J P
Marion Merrel Dow Inc., Kansas City, Mo.
Haemostasis. 1990;20(6):334-40. doi: 10.1159/000216147.
Fibrolase, a direct-acting fibrinolytic enzyme has been shown to cleave primarily the A alpha and B beta chains of human fibrin. We have previously reported that fibrolase also exhibits fibrinogenolytic activity and acts mainly as an alpha-chain fibrinogenase. In contrast to the action of streptokinase (plasminogen activator), fibrolase does not activate plasminogen. In vitro thrombolytic efficacy of fibrolase was determined by monitoring the release of radiolabel from iodinated fibrin and human blood clots. Fibrolase effectively digested the clots in a dose-dependent manner. The in vivo efficacy of fibrolase was evaluated in an animal model of arterial thrombosis. Fibrolase was found to be efficacious at dissolving femoral arterial clots following a single intravenous bolus administration. Time to reperfusion was dose dependent and similar to that observed with streptokinase. No adverse effects on blood pressure and heart rate were observed.
纤维蛋白酶是一种直接作用的纤溶酶,已被证明主要裂解人纤维蛋白的Aα链和Bβ链。我们之前曾报道,纤维蛋白酶还具有纤维蛋白原溶解活性,主要作为α链纤维蛋白原酶发挥作用。与链激酶(纤溶酶原激活剂)的作用不同,纤维蛋白酶不激活纤溶酶原。通过监测放射性标记从碘化纤维蛋白和人血凝块中的释放来确定纤维蛋白酶的体外溶栓效果。纤维蛋白酶以剂量依赖的方式有效消化血凝块。在动脉血栓形成的动物模型中评估了纤维蛋白酶的体内效果。发现单次静脉推注给药后,纤维蛋白酶在溶解股动脉血栓方面有效。再灌注时间呈剂量依赖性,与链激酶观察到的情况相似。未观察到对血压和心率的不良影响。